How petrelintide’s tolerability profile could reshape patient adherence in obesity pharmacotherapy

Zealand Pharma A/S (NASDAQ: ZEAL) strengthened its position in the intensifying obesity drug race after reporting Phase 2 results showing that its investigational amylin analog petrelintide delivered double-digit weight loss with tolerability levels comparable to placebo. The findings from the ZUPREME-1 study move the once-weekly therapy closer to Phase 3 development and reinforce the strategic rationale behind Zealand Pharma A/S’s collaboration with Roche to pursue a larger role in the rapidly expanding global obesity therapeutics market.

The announcement also underscores how the competitive dynamics of metabolic drug development are beginning to evolve beyond the first wave of incretin therapies. While GLP-1 drugs have reshaped obesity treatment and investor expectations for the sector, pharmaceutical companies are increasingly exploring complementary biological pathways that could improve treatment persistence, broaden patient eligibility, and support future combination therapy strategies. Within that shifting landscape, amylin-based drugs such as petrelintide are emerging as one of the more closely watched alternatives to the incretin-dominated model currently defining obesity pharmacotherapy.

Why are pharmaceutical companies increasingly exploring non-GLP-1 mechanisms like amylin analogs for obesity treatment?

The obesity drug market has rapidly consolidated around incretin biology. Therapies targeting glucagon-like peptide-1 receptors and related pathways dominate current treatment strategies because they suppress appetite and improve glucose metabolism. However, their rapid adoption has also exposed certain limitations that drug developers are now attempting to address.

One challenge involves tolerability. Gastrointestinal side effects remain common in incretin therapy, particularly during dose escalation periods. Although many patients ultimately tolerate treatment, nausea, vomiting, and other digestive symptoms can affect adherence and sometimes lead to discontinuation. In a chronic disease such as obesity, where treatment may continue for years, even modest tolerability improvements can influence prescribing behavior.

Amylin biology offers a potential alternative. Amylin is a hormone released alongside insulin by pancreatic beta cells and plays a role in regulating appetite and satiety. By mimicking amylin signaling, therapies such as petrelintide aim to reduce food intake through neural pathways distinct from those used by incretin drugs.

For pharmaceutical strategists, this difference is important because it opens two possible paths. Amylin therapies could function as stand-alone obesity treatments, or they could be combined with incretin drugs to enhance weight loss while distributing side-effect risk across multiple mechanisms. In either scenario, a therapy that achieves meaningful weight reduction without worsening tolerability could gain traction among clinicians and patients.

How does the ZUPREME-1 trial data position petrelintide within the competitive obesity drug pipeline?

The ZUPREME-1 trial enrolled 493 participants with overweight or obesity and evaluated once-weekly subcutaneous injections of petrelintide across several dose levels. Participants had a mean baseline body mass index of roughly 37 kilograms per square meter, representing a patient population commonly included in obesity pharmacotherapy studies.

Across treatment groups, petrelintide produced statistically significant weight reduction compared with placebo after 28 weeks, with sustained effects through week 42. At the most effective dose, participants achieved an average body weight reduction of 10.7 percent. This magnitude of weight loss places the therapy within the range considered clinically meaningful in obesity treatment.

However, the most closely watched result involved tolerability rather than efficacy alone. In the highest-efficacy treatment arm, investigators reported no cases of vomiting and no treatment discontinuations due to gastrointestinal adverse events. The rate of discontinuation due to adverse events remained similar between petrelintide and placebo groups, suggesting the therapy may avoid some of the tolerability challenges observed in other weight-loss drugs.

Researchers believe the dosing strategy used in the study contributed to these outcomes. Petrelintide doses were escalated gradually every four weeks, a slower schedule than earlier studies. Clinicians monitoring the program suggest this approach may reduce early treatment intolerance and improve the likelihood that patients remain on therapy long enough to reach maintenance dosing.

How could long-term patient persistence become the decisive commercial variable in the obesity pharmacotherapy market?

Efficacy is only one part of the equation in obesity pharmacotherapy. Long-term adherence has emerged as a critical variable shaping both clinical outcomes and commercial success. Patients frequently discontinue weight-loss medications due to side effects, cost, or perceived lack of benefit.

The ZUPREME-1 data indicate that petrelintide may address at least one of those factors. Nearly all participants in the highest efficacy arm successfully escalated to the target maintenance dose. High completion rates during dose escalation suggest that the therapy may be manageable for patients during the period when treatment discontinuation most often occurs.

For healthcare providers, this distinction matters because obesity management increasingly resembles chronic disease treatment rather than short-term intervention. Therapies capable of maintaining patient adherence over longer periods may ultimately deliver greater cumulative weight loss even if initial efficacy is similar to competing drugs.

Industry observers note that adherence could become one of the main differentiators in the obesity market as more therapies reach commercialization. Physicians treating metabolic disease often prioritize medications that patients can realistically remain on for extended periods. A therapy that combines meaningful weight reduction with improved tolerability therefore has a clearer path toward sustained clinical adoption.

How does Zealand Pharma’s collaboration with Roche influence the commercial outlook for petrelintide?

Another factor shaping the program’s prospects is Zealand Pharma A/S’s partnership with Roche. The two companies entered a collaboration and licensing agreement to co-develop and commercialize petrelintide for chronic weight management.

Such alliances are common in obesity drug development because late-stage clinical trials require substantial financial resources and global infrastructure. Large pharmaceutical companies bring regulatory expertise, manufacturing scale, and international commercial networks that biotechnology firms often lack.

Roche’s involvement could therefore accelerate Phase 3 development and help position the therapy for global regulatory submissions if clinical results continue to meet expectations. The collaboration also signals confidence from a large pharmaceutical partner that the amylin pathway represents a viable opportunity in metabolic disease.

Beyond monotherapy development, the partnership may support combination therapy strategies. Zealand Pharma has indicated plans to evaluate petrelintide alongside other metabolic therapies, including investigational incretin drugs. If successful, such combinations could deliver greater weight reduction than single-agent therapies while balancing safety profiles across mechanisms.

What upcoming clinical milestones will determine whether petrelintide can compete with established obesity drugs?

The next stage of development will determine whether petrelintide can convert promising Phase 2 signals into regulatory approval and commercial viability. Zealand Pharma A/S is expected to initiate Phase 3 trials after refining dose selection and study design using insights from the ZUPREME-1 results.

Another critical milestone involves the ZUPREME-2 trial, a second Phase 2 study evaluating petrelintide monotherapy in individuals with overweight or obesity who also have type 2 diabetes. Results from this study are expected later in 2026 and may clarify how the therapy performs in patients with more complex metabolic conditions.

Regulatory agencies will also focus on durability of weight loss and long-term safety. Obesity therapies must demonstrate sustained benefit over extended treatment periods, often exceeding one year. Larger clinical populations are also necessary to detect rare adverse events that smaller Phase 2 trials cannot capture.

For investors and industry analysts, the central question is whether petrelintide can carve out a distinct position in a crowded therapeutic field. The obesity market may eventually support multiple mechanisms, particularly if combination therapy becomes standard practice. If Phase 3 trials confirm the tolerability advantages suggested by ZUPREME-1, petrelintide could become part of that emerging treatment landscape.

Key takeaways on what Zealand Pharma’s petrelintide results signal for the obesity drug industry

• Zealand Pharma A/S is advancing petrelintide toward Phase 3 after Phase 2 data showed double-digit weight loss and tolerability comparable to placebo.

• The therapy represents an amylin-based mechanism that could diversify obesity pharmacotherapy beyond incretin signaling.

• Strong tolerability signals may improve long-term patient adherence, a factor increasingly important in chronic obesity treatment.

• The collaboration between Zealand Pharma and Roche provides development funding and global commercialization infrastructure.

• Upcoming data from the ZUPREME-2 study will help clarify the therapy’s effectiveness in patients with type 2 diabetes.

• Larger Phase 3 trials will determine whether the therapy can sustain weight loss and maintain safety over extended treatment periods.

• If clinical results remain positive, amylin analog therapies could become complementary components of future combination obesity treatments.